The degree of pathway inhibition in T-ALL cells exposed to more selective PI3K p110α, β, and δ inhibitors was more heterogenenous (Fig 3B–3D) and supports the idea that different leukemias show variable dependence on each PI3K isoform to activate Akt. Here, PIK3CA is linked to acute lymphoblastic leukemia.